ClinicalTrials.gg
CompletedNCT02735044EDITION JUNIORUpdated Mar 25, 2022Results posted

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus

A Phase 3 interventional study of Insulin glargine,300 U/mL and Insulin glargine (100 units /mL) in Type 1 Diabetes Mellitus, sponsored by Sanofi. Completed at 107 sites in 24 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-03-25.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
463
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.

Enrollment
8th of 66
463 · median 73
Started
2016
with 1 other
Phase 3
18 of 66
none open now
Registered
49th of 66
by date
Lead sponsor
24 of 66
Sanofi

Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 8th largest by enrollment, is one of 2 that started in 2016, is one of 18 in phase 3, and was the 49th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

Primary Objective:

To compare the efficacy of a new formulation of insulin glargine (HOE901-U300) to Lantus in terms of change of HbA1c from baseline to endpoint (month 6) in children and adolescents with type 1 diabetes mellitus.

.

Secondary Objectives:

To compare HOE901-U300 and Lantus in terms of:

  • Percentage of participants reaching target HbA1c and fasting plasma glucose (FPG).
  • To assess the safety of HOE901-U300 including analysis of events of hypoglycemia, events of hyperglycemia with ketosis, and development of anti-insulin-antibodies.
Read the detailed description

The study duration per participant was approximately 58 weeks that consisted of a 2 week screening period, a main 6-month comparative efficacy and safety treatment period, a 6-month comparative safety extension period, and a 4-week post treatment follow up period.

03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and adolescents with type 1 diabetes mellitus (T1DM) for at least 1 year confirmed by typical symptoms at diagnosis and/or by antibody testing [presence of anti-GAD (glutamic acid decarboxylase) or anti-IA2 (islet antigen 2/tyrosine phosphatase) or anti-islet cell antibodies] and/or clinical features (eg, history of ketoacidosis)].
  • Signed written obtained from parent(s)/legal guardian and written or oral assent obtained from participant.

Exclusion criteria

Exclusion criteria:

  • Age \<6 years and >=18 years at randomization.
  • Less than 1 year on insulin treatment prior to screening visit.
  • Less than 6 months on basal plus mealtime insulin and self-monitoring of blood glucose prior to screening visit.
  • Participants using premix insulins in the last 3 months before screening visit or participants using human regular insulin as mealtime insulin in the last 3 months before screening visit.
  • Use of an insulin pump in the last 6 months before screening visit or plans to switch to pump within the next 6 months after screening visit.
  • Any to use of insulin glargine as defined in the national product label.
  • No willingness to inject insulin glargine (Lantus or HOE901-U300) once daily.
  • \<7.5% or >11% at screening.
  • Initiation of any glucose-lowering medications in the last 3 months before screening visit.
  • Hospitalization or care in the emergency ward for diabetic ketoacidosis or history of severe hypoglycemia (as defined by need for glucagon or IV glucose) and accompanied by seizure and/or unconsciousness and/or coma in the last 3 months prior to screening visit.
  • Postmenarchal girls not protected by highly-effective method(s) of and/or who were unwilling or unable to be tested for pregnancy. Abstinence from sexual intercourse was considered as an acceptable form of birth control.
  • Pregnant or breast-feeding adolescents, or adolescents who intended to become pregnant during the study period, or who were at risk of getting pregnant due to any psychosocial reason during the study period.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
463 participants (actual)

Study arms

  • Experimental
    HOE901-U300

    HOE901-U300 (Insulin glargine 300 Units/milliliter \[U/mL\]) Subcutaneous(SC) injection once daily for 12 months.

    Drug: Insulin glargine,300 U/mL · Drug: Background therapy

  • Active comparator
    Lantus

    Lantus (Insulin glargine 100 U/mL) SC injection once daily for 12 months.

    Drug: Insulin glargine (100 units /mL) · Drug: Background therapy

Interventions

  • DrugInsulin glargine,300 U/mL

    Drug page: Insulin Glargine

    Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 milligram/deciliter (mg/dL) (5.0 to 7.2 millimol per liter \[mmol/L\])

    Also known as: Toujeo ®

  • DrugInsulin glargine (100 units /mL)

    Drug page: Insulin Glargine

    Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L)

  • DrugBackground therapy

    Fast-acting mealtime insulin analogs

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c to Month 6

    Change in HbA1c was calculated by subtracting baseline value from Month 6 value. Adjusted least-square (LS) means and standard errors (SE) were obtained using analysis of covariance (ANCOVA) after multiple imputations of missing data using post-baseline HbA1c data available on the main 6-month randomized period.

    Time frame: Baseline to Month 6

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG) to Month 6

    Change in FPG was calculated by subtracting baseline value from Month 6 value. Adjusted LS means and SE were obtained using ANCOVA after multiple imputation to address missing data in the main 6 month randomized period.

    Time frame: Baseline to Month 6

  2. Percentage of Participants With HbA1c Values of <7.5% at Month 6

    Participants without any available HbA1c assessment at month 6 and/or with a premature study discontinuation during the main 6-month randomized period were considered as a failure (non-responders) in the analysis. Analysis was performed using Cochran-Mantel-Haenszel (CMH) method with randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).

    Time frame: Month 6

  3. Percentage of Participants With HbA1c Values of <7.5% Without Any Episode of Severe and/or Documented Self-Monitored Plasma Glucose ([SMPG] <54 mg/dL [3.0 mmol/L]) Symptomatic Hypoglycemia During the Last 3 Months of the Main 6-month Randomized Period

    Participants without any available HbA1c assessment at month 6 and/or with a premature study discontinuation during the main 6-month randomized period were considered as a failure (non-responders) in the analysis. Analysis was performed using Cochran-Mantel-Haenszel (CMH) method with randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).

    Time frame: upto Month 6

  4. Percentage of Participants With FPG of <=130 mg/dL (7.2 mmol/L) at Month 6

    Participants without any available FPG assessment at month 6 and/or with a premature study discontinuation during the main 6-month randomized period were considered as a failure (non-responders) in the analysis. Analysis was performed using Cochran-Mantel-Haenszel (CMH) method with randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).

    Time frame: Month 6

  5. Percentage of Participants With FPG of <=130 mg/dL (7.2 mmol/L) Without Any Episode of Severe and/or Documented (SMPG <54 mg/dL [3.0 mmol/L]) Symptomatic Hypoglycemia During the Last 3 Months of the Main 6-month Randomized Period

    Participants without any available HbA1c assessment at month 6 and/or with a premature study discontinuation during the main 6-month randomized period were considered as a failure (non-responders) in the analysis. Analysis was performed using Cochran-Mantel-Haenszel (CMH) method with randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).

    Time frame: upto Month 6

  6. Change From Baseline in 24-Hour Mean Plasma Glucose Based on 8-point SMPG Profiles to Month 6

    8-point SMPG profiles were measured at the following 8 points: between 01:00 and 04:00 (clock time) at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime. Analysis was performed using a ANCOVA model including the fixed categorical effects of treatment group, randomization strata of screening HbA1c (\<8.5%; \>=8.5%), randomization strata of age at screening (\<12 years, \>=12 years) and the baseline 24-hour average 8-point profile SMPG.

    Time frame: Baseline to Month 6

  7. Change From Baseline in Variability of 24-Hour Mean Plasma Glucose Based on 8-point SMPG Profiles at Month 6

    8-point SMPG profiles were measured at the following 8 points: between 01:00 and 04:00 (clock time) at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime. Variability was assessed by the coefficient of variation (standard deviation divided by mean) calculated over the 8-point SMPG. Analysis was performed using a ANCOVA model including the fixed categorical effects of treatment group, randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).

    Time frame: Baseline, Month 6

  8. Change From Baseline to Month 6 in 8-Point SMPG Profile Per Time Point

    8-point SMPG profiles were measured for following 8 time points at Baseline and Month 6: between 01:00 and 04:00 (clock time) at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime.

    Time frame: Baseline to Month 6

  9. Percentage of Participants With at Least One Hypoglycemic Events (Any Hypoglycemia, Severe Hypoglycemia, Documented Symptomatic, Probable Symptomatic, Asymptomatic Hypoglycemia, Pseudo-hypoglycemia and Severe and/or Confirmed Hypoglycemia) at Month 12

    Severe hypoglycemia: an event in which the child/adolescent having altered mental status and cannot assist in their care, is semiconscious or unconscious, or in coma ± convulsions and may require parenteral therapy (glucagon or glucose). Documented symptomatic hypoglycemia: an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<=70 mg/dL (3.9 mmol/L). Asymptomatic hypoglycemia: an event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration \<=70 mg/dL. Probable symptomatic hypoglycemia: an event during which symptoms of hypoglycemia were not accompanied by plasma glucose determination but was presumably caused by a plasma glucose concentration \<=70 mg/dL. Pseudo-hypoglycemia:an event with any of the typical symptoms of hypoglycaemia with plasma glucose concentration \>70 mg/dL.

    Time frame: Month 12

  10. Percentage of Participants With Any Hyperglycemia With Ketosis at Month 12

    Hyperglycemia with ketosis was defined as SMPG \>=252 mg/dL (14 mmol/L) with accompanying self-measured blood ketones \>=1.5 mmol/L.

    Time frame: Month 12

07

Results

Posted Jun 19, 2019
Limitations and caveats
None reported

Participant flow

The study was conducted at 105 centers in 24 countries. A total of 616 participants were screened between 14 April 2016 and 31 October 2017, of which 153 were screen failures. Screen failures were mainly due to glycated hemoglobin (HbA1c) level outside of defined ranges per eligibility criteria.

Participant flow — Overall Study
MilestoneHOE901-U300Lantus
Started233230
Treated233228
Completed217207
Not completed1623
Withdrew: Adverse event33
Withdrew: Lack of efficacy10
Withdrew: Poor compliance to protocol77
Withdrew: Randomized and not treated02
Withdrew: Other, not specified above511

Outcome measures

PrimaryChange From Baseline in HbA1c to Month 6

Change in HbA1c was calculated by subtracting baseline value from Month 6 value. Adjusted least-square (LS) means and standard errors (SE) were obtained using analysis of covariance (ANCOVA) after multiple imputations of missing data using post-baseline HbA1c data available on the main 6-month randomized period.

Time frame:
Baseline to Month 6
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in HbA1c to Month 6
Percentage of HbA1cHOE901-U300Lantus
Change From Baseline in HbA1c to Month 6-0.399 ± 0.063-0.402 ± 0.064
Statistical analysis
  • HOE901-U300 vs Lantus · Ls mean difference: 0.004 · 95% CI -0.172 to 0.179
  • HOE901-U300 vs Lantus · ANCOVA · p = 0.965 (Threshold for significance at 0.025 level.)
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) to Month 6

Change in FPG was calculated by subtracting baseline value from Month 6 value. Adjusted LS means and SE were obtained using ANCOVA after multiple imputation to address missing data in the main 6 month randomized period.

Time frame:
Baseline to Month 6
Reported as:
Least squares mean · millimole per liter (mmol/L)
Change From Baseline in Fasting Plasma Glucose (FPG) to Month 6
millimole per liter (mmol/L)HOE901-U300Lantus
Change From Baseline in Fasting Plasma Glucose (FPG) to Month 6-0.563 ± 0.372-0.549 ± 0.372
SecondaryPercentage of Participants With HbA1c Values of <7.5% at Month 6

Participants without any available HbA1c assessment at month 6 and/or with a premature study discontinuation during the main 6-month randomized period were considered as a failure (non-responders) in the analysis. Analysis was performed using Cochran-Mantel-Haenszel (CMH) method with randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).

Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c Values of <7.5% at Month 6
percentage of participantsHOE901-U300Lantus
Percentage of Participants With HbA1c Values of <7.5% at Month 626.1823.48
SecondaryPercentage of Participants With HbA1c Values of <7.5% Without Any Episode of Severe and/or Documented Self-Monitored Plasma Glucose ([SMPG] <54 mg/dL [3.0 mmol/L]) Symptomatic Hypoglycemia During the Last 3 Months of the Main 6-month Randomized Period

Participants without any available HbA1c assessment at month 6 and/or with a premature study discontinuation during the main 6-month randomized period were considered as a failure (non-responders) in the analysis. Analysis was performed using Cochran-Mantel-Haenszel (CMH) method with randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).

Time frame:
upto Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c Values of <7.5% Without Any Episode of Severe and/or Documented Self-Monitored Plasma Glucose ([SMPG] <54 mg/dL [3.0 mmol/L]) Symptomatic Hypoglycemia During the Last 3 Months of the Main 6-month Randomized Period
percentage of participantsHOE901-U300Lantus
Percentage of Participants With HbA1c Values of <7.5% Without Any Episode of Severe and/or Documented Self-Monitored Plasma Glucose ([SMPG] <54 mg/dL [3.0 mmol/L]) Symptomatic Hypoglycemia During the Last 3 Months of the Main 6-month Randomized Period4.294.78
SecondaryPercentage of Participants With FPG of <=130 mg/dL (7.2 mmol/L) at Month 6

Participants without any available FPG assessment at month 6 and/or with a premature study discontinuation during the main 6-month randomized period were considered as a failure (non-responders) in the analysis. Analysis was performed using Cochran-Mantel-Haenszel (CMH) method with randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).

Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With FPG of <=130 mg/dL (7.2 mmol/L) at Month 6
percentage of participantsHOE901-U300Lantus
Percentage of Participants With FPG of <=130 mg/dL (7.2 mmol/L) at Month 627.4726.52
SecondaryPercentage of Participants With FPG of <=130 mg/dL (7.2 mmol/L) Without Any Episode of Severe and/or Documented (SMPG <54 mg/dL [3.0 mmol/L]) Symptomatic Hypoglycemia During the Last 3 Months of the Main 6-month Randomized Period

Participants without any available HbA1c assessment at month 6 and/or with a premature study discontinuation during the main 6-month randomized period were considered as a failure (non-responders) in the analysis. Analysis was performed using Cochran-Mantel-Haenszel (CMH) method with randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).

Time frame:
upto Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With FPG of <=130 mg/dL (7.2 mmol/L) Without Any Episode of Severe and/or Documented (SMPG <54 mg/dL [3.0 mmol/L]) Symptomatic Hypoglycemia During the Last 3 Months of the Main 6-month Randomized Period
percentage of participantsHOE901-U300Lantus
Percentage of Participants With FPG of <=130 mg/dL (7.2 mmol/L) Without Any Episode of Severe and/or Documented (SMPG <54 mg/dL [3.0 mmol/L]) Symptomatic Hypoglycemia During the Last 3 Months of the Main 6-month Randomized Period9.447.39
SecondaryChange From Baseline in 24-Hour Mean Plasma Glucose Based on 8-point SMPG Profiles to Month 6

8-point SMPG profiles were measured at the following 8 points: between 01:00 and 04:00 (clock time) at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime. Analysis was performed using a ANCOVA model including the fixed categorical effects of treatment group, randomization strata of screening HbA1c (\<8.5%; \>=8.5%), randomization strata of age at screening (\<12 years, \>=12 years) and the baseline 24-hour average 8-point profile SMPG.

Time frame:
Baseline to Month 6
Reported as:
Least squares mean · mmol/L
Change From Baseline in 24-Hour Mean Plasma Glucose Based on 8-point SMPG Profiles to Month 6
mmol/LHOE901-U300Lantus
Change From Baseline in 24-Hour Mean Plasma Glucose Based on 8-point SMPG Profiles to Month 60.139 ± 0.249-0.266 ± 0.250
SecondaryChange From Baseline in Variability of 24-Hour Mean Plasma Glucose Based on 8-point SMPG Profiles at Month 6

8-point SMPG profiles were measured at the following 8 points: between 01:00 and 04:00 (clock time) at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime. Variability was assessed by the coefficient of variation (standard deviation divided by mean) calculated over the 8-point SMPG. Analysis was performed using a ANCOVA model including the fixed categorical effects of treatment group, randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percentage of mean variability
Change From Baseline in Variability of 24-Hour Mean Plasma Glucose Based on 8-point SMPG Profiles at Month 6
percentage of mean variabilityHOE901-U300Lantus
Change From Baseline in Variability of 24-Hour Mean Plasma Glucose Based on 8-point SMPG Profiles at Month 61.469 ± 1.4090.789 ± 1.415
SecondaryChange From Baseline to Month 6 in 8-Point SMPG Profile Per Time Point

8-point SMPG profiles were measured for following 8 time points at Baseline and Month 6: between 01:00 and 04:00 (clock time) at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime.

Time frame:
Baseline to Month 6
Reported as:
Mean · mmol/L
Change From Baseline to Month 6 in 8-Point SMPG Profile Per Time Point
mmol/LHOE901-U300Lantus
Between 01:00 and 04:00 at night0.84 ± 6.94-0.60 ± 7.08
Pre-breakfast-0.41 ± 5.48-1.71 ± 6.56
2 hours after breakfast-0.26 ± 7.18-0.62 ± 6.78
Pre-lunch0.43 ± 6.991.11 ± 6.85
2 hours after lunch0.49 ± 7.64-0.55 ± 7.20
Pre-dinner0.29 ± 8.05-0.02 ± 6.78
2 hours after dinner0.51 ± 8.530.60 ± 6.86
Bedtime0.86 ± 7.60-0.60 ± 7.00
SecondaryPercentage of Participants With at Least One Hypoglycemic Events (Any Hypoglycemia, Severe Hypoglycemia, Documented Symptomatic, Probable Symptomatic, Asymptomatic Hypoglycemia, Pseudo-hypoglycemia and Severe and/or Confirmed Hypoglycemia) at Month 12

Severe hypoglycemia: an event in which the child/adolescent having altered mental status and cannot assist in their care, is semiconscious or unconscious, or in coma ± convulsions and may require parenteral therapy (glucagon or glucose). Documented symptomatic hypoglycemia: an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<=70 mg/dL (3.9 mmol/L). Asymptomatic hypoglycemia: an event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration \<=70 mg/dL. Probable symptomatic hypoglycemia: an event during which symptoms of hypoglycemia were not accompanied by plasma glucose determination but was presumably caused by a plasma glucose concentration \<=70 mg/dL. Pseudo-hypoglycemia:an event with any of the typical symptoms of hypoglycaemia with plasma glucose concentration \>70 mg/dL.

Time frame:
Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Hypoglycemic Events (Any Hypoglycemia, Severe Hypoglycemia, Documented Symptomatic, Probable Symptomatic, Asymptomatic Hypoglycemia, Pseudo-hypoglycemia and Severe and/or Confirmed Hypoglycemia) at Month 12
percentage of participantsHOE901-U300Lantus
Any hypoglycemia99.198.7
Severe Hypoglycemia8.611.0
Documented Symptomatic Hypoglycemia94.893.9
Probable Symptomatic Hypoglycemia10.313.6
Asymptomatic Hypoglycemia88.489.5
Pseudo-hypoglycemia15.914.5
Severe and/or documented hypoglycemia99.198.2
SecondaryPercentage of Participants With Any Hyperglycemia With Ketosis at Month 12

Hyperglycemia with ketosis was defined as SMPG \>=252 mg/dL (14 mmol/L) with accompanying self-measured blood ketones \>=1.5 mmol/L.

Time frame:
Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With Any Hyperglycemia With Ketosis at Month 12
percentage of participantsHOE901-U300Lantus
Percentage of Participants With Any Hyperglycemia With Ketosis at Month 129.913.6

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form until the end of the study (Week 58) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HOE901-U3001/233 (0.4%)35/233 (15%)105/233 (45.1%)
Lantus0/228 (0%)31/228 (13.6%)118/228 (51.8%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventHOE901-U300Lantus
Hypoglycaemic SeizureNervous system disorders8/23310/228
Hypoglycaemic UnconsciousnessNervous system disorders6/23310/228
Diabetic KetoacidosisMetabolism and nutrition disorders5/2336/228
Alanine Aminotransferase IncreasedInvestigations3/2331/228
AppendicitisInfections and infestations1/2332/228
Diabetes Mellitus Inadequate ControlMetabolism and nutrition disorders2/2332/228
HypoglycaemiaMetabolism and nutrition disorders2/2330/228
Adrenal InsufficiencyEndocrine disorders0/2331/228
GastroenteritisInfections and infestations1/2331/228
Meningococcal InfectionInfections and infestations0/2331/228
Most frequent other events
Most frequent other events
EventHOE901-U300Lantus
NasopharyngitisInfections and infestations37/23339/228
KetosisMetabolism and nutrition disorders19/23330/228
PharyngitisInfections and infestations14/23322/228
Upper Respiratory Tract InfectionInfections and infestations20/23318/228
InfluenzaInfections and infestations14/23319/228
HeadacheNervous system disorders19/23315/228
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders15/2337/228
VomitingGastrointestinal disorders14/2339/228
OverweightMetabolism and nutrition disorders2/23313/228
GastroenteritisInfections and infestations12/23310/228

Baseline characteristics

Analysis was performed on all randomized participants.

Age, Continuous
Age, Continuous(Years)HOE901-U300LantusTotal
Mean12.9 ± 2.912.9 ± 2.912.9 ± 2.9
Sex: Female, Male
Sex: Female, Male(Participants)HOE901-U300LantusTotal
Female105121226
Male128109237
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HOE901-U300LantusTotal
American Indian or Alaska Native000
Asian11617
Native Hawaiian or Other Pacific Islander000
Black or African American8614
White211211422
More than one race224
Unknown or Not Reported011
Body Mass Index (BMI)
Body Mass Index (BMI)(BMI percentile)HOE901-U300LantusTotal
Mean67.52 ± 26.6269.13 ± 26.6468.32 ± 26.61
Hemoglobin A1C (HbA1C)
Hemoglobin A1C (HbA1C)(percentage of A1C)HOE901-U300LantusTotal
Mean8.65 ± 0.888.61 ± 0.878.63 ± 0.88
08

Study locations

107 sites
  • Investigational Site Number 8400008
    Tucson, Arizona 85724, United States
  • Investigational Site Number 8400037
    Atlanta, Georgia 30318, United States
  • Investigational Site Number 8400032
    Indianapolis, Indiana 46202, United States
  • Investigational Site Number 8400015
    Buffalo, New York 14222, United States
  • Investigational Site Number 8400016
    Chapel Hill, North Carolina 27599-7295, United States
  • Investigational Site Number 8400035
    Morehead City, North Carolina 28557, United States
  • Investigational Site Number 8400038
    Oklahoma City, Oklahoma 73112, United States
  • Investigational Site Number 8400030
    Philadelphia, Pennsylvania 19104, United States
  • Investigational Site Number 8400010
    Rapid City, South Dakota 57701, United States
  • Investigational Site Number 8400005
    Dallas, Texas 75231, United States
  • Investigational Site Number 8400021
    Dallas, Texas 75235, United States
  • Investigational Site Number 8400029
    Lufkin, Texas 75904, United States
  • Investigational Site Number 8400034
    Seattle, Washington 98105, United States
  • Investigational Site Number 0320003
    Caba, C1180AAX, Argentina
  • Investigational Site Number 0320001
    Caba, C1270AAN, Argentina
  • Investigational Site Number 0320004
    Capital Federal, C1179AAB, Argentina
  • Investigational Site Number 0320002
    Capital Federal, C1425DUC, Argentina
  • Investigational Site Number 0320006
    Mendoza, 5500, Argentina
  • Investigational Site Number 0320005
    Salta, 4400, Argentina
  • Investigational Site Number 0320007
    San Miguel De Tucuman, 4107, Argentina
  • Investigational Site Number 0760005
    Curitiba, 80810-040, Brazil
  • Investigational Site Number 0760006
    Fortaleza, 60115-282, Brazil
  • Investigational Site Number 0760004
    Fortaleza, 60430-350, Brazil
  • Investigational Site Number 0760003
    Porto Alegre, 91350-250, Brazil
  • Investigational Site Number 0760001
    Sao Paulo, 04022-001, Brazil
  • Investigational Site Number 0760002
    Sao Paulo, Brazil
  • Investigational Site Number 1000001
    Plovdiv, 4000, Bulgaria
  • Investigational Site Number 1000005
    Sofia, 1784, Bulgaria
  • Investigational Site Number 1000004
    Varna, 9000, Bulgaria
  • Investigational Site Number 1240003
    Halifax, B3K6R8, Canada
  • Investigational Site Number 1240002
    Montreal, H1T 2M4, Canada
  • Investigational Site Number 1240005
    Montreal, H3T 1C5, Canada
  • Investigational Site Number 1240006
    Sherbrooke, J1H 5N4, Canada
  • Investigational Site Number 1520002
    Santiago, 8207257, Chile
  • Investigational Site Number 1520004
    Santiago, 8330074, Chile
  • Investigational Site Number 1520006
    Santiago, Chile
  • Investigational Site Number 1520007
    Temuco, 4813299, Chile
  • Investigational Site Number 1520003
    Viña Del Mar, Chile
  • Investigational Site Number 2030003
    Hradec Kralove, 500 05, Czechia
  • Investigational Site Number 2030005
    Ostrava - Poruba, 70852, Czechia
  • Investigational Site Number 2030001
    Praha 5 - Motol, 15006, Czechia
  • Investigational Site Number 2080001
    Herlev, 2730, Denmark
  • Investigational Site Number 2500003
    Montpellier, 34295, France
  • Investigational Site Number 2500002
    Toulouse, 31059, France
  • Investigational Site Number 2760002
    Hannover, 30173, Germany
  • Investigational Site Number 2760001
    Heidelberg, 69120, Germany
  • Investigational Site Number 2760004
    Leipzig, 04103, Germany
  • Investigational Site Number 2760003
    Münster, 48155, Germany
  • Investigational Site Number 3480001
    Budapest, 1036, Hungary
  • Investigational Site Number 3480004
    Budapest, 1083, Hungary
  • Investigational Site Number 3480003
    Budapest, 1089, Hungary
  • Investigational Site Number 3480005
    Gyula, 5700, Hungary
  • Investigational Site Number 3480002
    Miskolc, 3529, Hungary
  • Investigational Site Number 3480006
    Pécs, 7623, Hungary
  • Investigational Site Number 3480007
    Székesfehérvár, 8000, Hungary
  • Investigational Site Number 3760003
    Beer Sheva, 84101, Israel
  • Investigational Site Number 3760001
    Haifa, 31096, Israel
  • Investigational Site Number 3760006
    Holon, 58100, Israel
  • Investigational Site Number 3760002
    Petach Tikva, Israel
  • Investigational Site Number 3800001
    Firenze, 50139, Italy
  • Investigational Site Number 3800005
    Roma, 00165, Italy
  • Investigational Site Number 3800004
    Torino, 10126, Italy
  • Investigational Site Number 3800006
    Varese, 21100, Italy
  • Investigational Site Number 3800003
    Verona, 37134, Italy
  • Investigational Site Number 3920006
    Chiyoda-Ku, Japan
  • Investigational Site Number 3920002
    Fukuoka-Shi, Japan
  • Investigational Site Number 3920003
    Hiroshima-Shi, Japan
  • Investigational Site Number 3920007
    Kobe-Shi, Japan
  • Investigational Site Number 3920005
    Osaka-Shi, Japan
  • Investigational Site Number 3920004
    Shinjuku-Ku, Japan
  • Investigational Site Number 4280002
    Daugavpils, LV-5417, Latvia
  • Investigational Site Number 4280001
    Rīga, LV-1004, Latvia
  • Investigational Site Number 4840003
    Durango, 34000, Mexico
  • Investigational Site Number 4840001
    Monterrey, 64460, Mexico
  • Investigational Site Number 4840004
    México, 06700, Mexico
  • Investigational Site Number 4840002
    Puebla, 72190, Mexico
  • Investigational Site Number 4840005
    Veracruz, 91910, Mexico
  • Investigational Site Number 8070001
    Skopje, 1000, North Macedonia
  • Investigational Site Number 6160005
    Bielsko-Biala, 43-316, Poland
  • Investigational Site Number 6160001
    Gdansk, 80-952, Poland
  • Investigational Site Number 6160006
    Szczecin, 71-252, Poland
  • Investigational Site Number 6160007
    Warszawa, 02-091, Poland
  • Investigational Site Number 6160004
    Warszawa, 04-730, Poland
  • Investigational Site Number 6160003
    Warszawa, 04-736, Poland
  • Investigational Site Number 6420005
    Bucharest, 041451, Romania
  • Investigational Site Number 6420007
    Constanta, 900591, Romania
  • Investigational Site Number 6420004
    Craiova, 200542, Romania
  • Investigational Site Number 6420006
    Sibiu, 550166, Romania
  • Investigational Site Number 6420003
    Timisoara, 300011, Romania
  • Investigational Site Number 6430001
    Moscow, 117036, Russian Federation
  • Investigational Site Number 6430004
    Smolensk, 214018, Russian Federation
  • Investigational Site Number 6430002
    St-Petersburg, 193144, Russian Federation
  • Investigational Site Number 6430003
    Ufa, 450000, Russian Federation
  • Investigational Site Number 6880002
    Belgrade, 11000, Serbia
  • Investigational Site Number 6880003
    Belgrade, 11000, Serbia
  • Investigational Site Number 6880004
    Nis, 18000, Serbia
  • Investigational Site Number 7240005
    Barcelona, 08035, Spain
  • Investigational Site Number 7240002
    Barcelona, 08041, Spain
  • Investigational Site Number 7240003
    Esplugues De Llobregat, 08950, Spain
  • Investigational Site Number 7240004
    Sabadell, 08208, Spain

Showing the first 100 of 107 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Danne T, Tamborlane WV, Malievsky OA, Franco DR, Kawamura T, Demissie M, Niemoeller E, Goyeau H, Wardecki M, Battelino T. Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial. Diabetes Care. 2020 Jul;43(7):1512-1519. doi: 10.2337/dc19-1926. Epub 2020 May 19. PubMed 32430458 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in May 2018, 25 months.

Results were first posted in Jun 2019, 1 year after primary completion.

Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 25 months is above that.

Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2016
First posted
Apr 12, 2016
StartActual
Apr 14, 2016
Primary completionActual
May 31, 2018
CompletionActual
Dec 20, 2018
Results first posted
Jun 19, 2019
Last update
Mar 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02735044
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 12, 2016
Start date
Apr 14, 2016
Primary completion
May 31, 2018
Completion
Dec 20, 2018
Results posted
Jun 19, 2019
Last update
Mar 25, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion